Research Analysts Offer Predictions for ABT Q3 Earnings

Abbott Laboratories (NYSE:ABT) – Investment analysts at William Blair boosted their Q3 2025 EPS estimates for shares of Abbott Laboratories in a research note issued on Thursday, April 17th. William Blair analyst M. Andrew now expects that the healthcare product maker will earn $1.33 per share for the quarter, up from their previous forecast of $1.32. The consensus estimate for Abbott Laboratories’ current full-year earnings is $5.14 per share. William Blair also issued estimates for Abbott Laboratories’ Q1 2026 earnings at $1.17 EPS, Q2 2026 earnings at $1.38 EPS, Q4 2026 earnings at $1.63 EPS and FY2026 earnings at $5.67 EPS.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The company had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.38 billion.

A number of other research analysts have also recently commented on ABT. StockNews.com lowered Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 12th. Royal Bank of Canada increased their target price on Abbott Laboratories from $140.00 to $145.00 and gave the stock an “outperform” rating in a research note on Thursday. Stifel Nicolaus lifted their target price on Abbott Laboratories from $135.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday. Raymond James increased their price target on shares of Abbott Laboratories from $132.00 to $142.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, Evercore ISI lifted their price objective on shares of Abbott Laboratories to $136.00 and gave the company a “buy” rating in a report on Thursday, January 2nd. Four investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $142.59.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $131.00 on Friday. Abbott Laboratories has a fifty-two week low of $99.71 and a fifty-two week high of $141.23. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. The company has a 50 day moving average price of $130.63 and a 200 day moving average price of $121.72. The stock has a market capitalization of $227.20 billion, a P/E ratio of 17.12, a PEG ratio of 2.52 and a beta of 0.80.

Institutional Investors Weigh In On Abbott Laboratories

Institutional investors and hedge funds have recently made changes to their positions in the business. Redwood Park Advisors LLC acquired a new stake in Abbott Laboratories during the 4th quarter worth approximately $25,000. Noble Wealth Management PBC acquired a new stake in shares of Abbott Laboratories during the fourth quarter worth $26,000. NewSquare Capital LLC grew its position in Abbott Laboratories by 78.4% in the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker’s stock valued at $27,000 after buying an additional 105 shares during the last quarter. WealthTrak Capital Management LLC acquired a new position in Abbott Laboratories in the 4th quarter valued at $28,000. Finally, Rialto Wealth Management LLC purchased a new position in Abbott Laboratories during the 4th quarter worth $29,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, EVP Andrea F. Wainer sold 949 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $138.17, for a total transaction of $131,123.33. Following the transaction, the executive vice president now owns 74,381 shares of the company’s stock, valued at $10,277,222.77. The trade was a 1.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Lisa D. Earnhardt sold 91,167 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $133.82, for a total value of $12,199,967.94. Following the completion of the sale, the executive vice president now directly owns 71,928 shares of the company’s stock, valued at $9,625,404.96. The trade was a 55.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 116,449 shares of company stock valued at $15,463,316 in the last ninety days. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be given a dividend of $0.59 per share. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.80%. Abbott Laboratories’s dividend payout ratio is presently 30.85%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.